Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Liabilities: 2011-2025

Historic Total Liabilities for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to $53.8 million.

  • Fennec Pharmaceuticals' Total Liabilities fell 16.13% to $53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.8 million, marking a year-over-year decrease of 16.13%. This contributed to the annual value of $50.8 million for FY2024, which is 32.04% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Total Liabilities is $53.8 million, which was up 2.70% from $52.3 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Total Liabilities high stood at $66.2 million for Q1 2024, and its period low was $2.9 million during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $52.3 million (2025), whereas its average is $48.2 million.
  • Per our database at Business Quant, Fennec Pharmaceuticals' Total Liabilities spiked by 340.15% in 2023 and then decreased by 21.00% in 2025.
  • Fennec Pharmaceuticals' Total Liabilities (Quarterly) stood at $7.0 million in 2021, then skyrocketed by 294.44% to $29.5 million in 2022, then surged by 30.43% to $38.5 million in 2023, then skyrocketed by 32.04% to $50.8 million in 2024, then decreased by 16.13% to $53.8 million in 2025.
  • Its Total Liabilities stands at $53.8 million for Q3 2025, versus $52.3 million for Q2 2025 and $52.3 million for Q1 2025.